Drug Eluting Stents: Trends in Use
A Survey of Sixty Interventional Cardiologists
Deliverable: Survey with key findings.
Study Description:
|
Topic |
Drug Eluting Stent Usage |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Interventional Cardiology |
|
Region |
United States and Europe |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: 20 minutes Size: 60 respondents Fielding Dates: January 3, 2008 to January 8, 2008 |
Objectives:
To understand trends in the use of drug eluting stents. Specifically to:
§ Determine the current use of drug eluting stents (DESs) in various patient types and lesion types.
· Investigate anticipated impact of COURAGE trial results on DES usage.
· Identify drivers of potential increases or decreases in use over the next two years.
§ Rank the importance of safety concerns regarding DESs.
§ Rank various factors in terms of their influence on DES product selection.
§ Evaluate DES products on these factors.
§ Determine effect of published data on possible uptake of Custom NX product, XTENT.
§ Compare and contrast responses between physicians from the
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Boston Scientific |
BSX |
Taxus |
|
Abbott |
ABT |
Xience |
|
Medtronic |
MDT |
Endeavor |
|
Cordis (Wyeth) |
N/A |
Cypher |
Inclusion Criteria and Respondent Demographics:
|
Inclusion Criteria
|
§ Board-certified or eligible (US only) interventional cardiologists § 40 from the United States, 20 from Europe § In practice between 2 and 30 years § Place at least 10 stents per month |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |